Soltis Investment Advisors LLC Has $2.88 Million Holdings in Zoetis Inc. $ZTS

Soltis Investment Advisors LLC lifted its stake in Zoetis Inc. (NYSE:ZTS) by 885.3% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 18,475 shares of the company’s stock after purchasing an additional 16,600 shares during the quarter. Soltis Investment Advisors LLC’s holdings in Zoetis were worth $2,881,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in ZTS. Nova Wealth Management Inc. bought a new stake in shares of Zoetis during the 1st quarter worth about $25,000. 1248 Management LLC acquired a new position in shares of Zoetis during the first quarter valued at about $27,000. Saudi Central Bank bought a new stake in shares of Zoetis in the 1st quarter worth approximately $29,000. Cornerstone Planning Group LLC lifted its position in Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock worth $30,000 after purchasing an additional 88 shares during the period. Finally, REAP Financial Group LLC boosted its position in shares of Zoetis by 201.5% during the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after acquiring an additional 131 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ZTS. JPMorgan Chase & Co. decreased their price objective on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a research note on Wednesday. Argus restated a “buy” rating and set a $190.00 target price on shares of Zoetis in a report on Tuesday, September 9th. Leerink Partnrs cut shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Stifel Nicolaus set a $140.00 price target on Zoetis in a report on Tuesday. Finally, Leerink Partners cut Zoetis from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Five analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $191.00.

Zoetis Stock Performance

ZTS opened at $120.47 on Thursday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. Zoetis Inc. has a 52-week low of $119.07 and a 52-week high of $181.85. The firm has a market cap of $53.39 billion, a P/E ratio of 20.73, a price-to-earnings-growth ratio of 2.31 and a beta of 0.90. The business’s fifty day moving average is $145.63 and its 200-day moving average is $153.01.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.08. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.42 billion. During the same period last year, the firm posted $1.58 earnings per share. Zoetis’s revenue was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date is Friday, October 31st. Zoetis’s payout ratio is presently 34.42%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.